Can gut microbiota throughout the first 10 years of life predict executive functioning in childhood?

Animal models suggest that the gut microbiota can influence cognitive development and functioning via various pathways. In line with that, a first human study found associations between infant fecal microbiota composition and cognition at 2 years of age. This longitudinal study investigated whether fecal microbiota composition in infancy and childhood is associated with executive functioning in childhood. We followed healthy individuals from birth to their 10th year of life. Executive functioning was assessed using the Digit Span working memory test at 10 years of age and the ecologically valid Behavior Rating Inventory for executive functioning at 8 and 10 years. Stool samples were collected at month 1, 3 and 4 as well as at 6 and 10 years. The V4 region of the 16S ribosomal RNA was analyzed to determine microbial composition at the genus level. Using established statistical techniques for microbiota analysis, we did not find associations between fecal microbiota composition and executive functioning after accounting for breastfeeding, maternal education, child sex and age. Our study results are most compatible with the absence or only a weak relationship between infant and childhood fecal microbiota composition and executive functioning in childhood in healthy community children

Can gut microbiota throughout the first 10 years of life predict executive functioning in childhood?

Animal models suggest that the gut microbiota can influence cognitive development and functioning via various pathways. In line with that, a first human study found associations between infant fecal microbiota composition and cognition at 2 years of age. This longitudinal study investigated whether fecal microbiota composition in infancy and childhood is associated with executive functioning in childhood. We followed healthy individuals from birth to their 10th year of life. Executive functioning was assessed using the Digit Span working memory test at 10 years of age and the ecologically valid Behavior Rating Inventory for executive functioning at 8 and 10 years. Stool samples were collected at month 1, 3 and 4 as well as at 6 and 10 years. The V4 region of the 16S ribosomal RNA was analyzed to determine microbial composition at the genus level. Using established statistical techniques for microbiota analysis, we did not find associations between fecal microbiota composition and executive functioning after accounting for breastfeeding, maternal education, child sex and age. Our study results are most compatible with the absence or only a weak relationship between infant and childhood fecal microbiota composition and executive functioning in childhood in healthy community children

New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19-A Large Postmortem and Clinical Analysis.

Critically ill COVID-19 patients are at high risk for venous thromboembolism (VTE), namely deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and death. The optimal anticoagulation strategy in critically ill patients with COVID-19 remains unknown. This study investigated the ante mortem incidence as well as postmortem prevalence of VTE, the factors predictive of VTE, and the impact of changed anticoagulation practice on patient survival. We conducted a consecutive retrospective analysis of postmortem COVID-19 (n = 64) and non-COVID-19 (n = 67) patients, as well as ante mortem COVID-19 (n = 170) patients admitted to the University Medical Center Hamburg-Eppendorf (Hamburg, Germany). Baseline patient characteristics, parameters related to the intensive care unit (ICU) stay, and the clinical and autoptic presence of VTE were evaluated and statistically compared between groups. The occurrence of VTE in critically ill COVID-19 patients is confirmed in both ante mortem (17%) and postmortem (38%) cohorts. Accordingly, comparing the postmortem prevalence of VTE between age- and sex-matched COVID-19 (43%) and non-COVID-19 (0%) cohorts, we found the statistically significant increased prevalence of VTE in critically ill COVID-19 cohorts (p = 0.001). A change in anticoagulation practice was associated with the statistically significant prolongation of survival time (HR: 2.55, [95% CI 1.41-4.61], p = 0.01) and a reduction in VTE occurrence (54% vs. 25%; p = 0.02). In summary, in the autopsy as well as clinical cohort of critically ill patients with COVID-19, we found that VTE was a frequent finding. A change in anticoagulation practice was associated with a statistically significantly prolonged survival time

New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19—A Large Postmortem and Clinical Analysis

Critically ill COVID-19 patients are at high risk for venous thromboembolism (VTE), namely deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and death. The optimal anticoagulation strategy in critically ill patients with COVID-19 remains unknown. This study investigated the ante mortem incidence as well as postmortem prevalence of VTE, the factors predictive of VTE, and the impact of changed anticoagulation practice on patient survival. We conducted a consecutive retrospective analysis of postmortem COVID-19 (n = 64) and non-COVID-19 (n = 67) patients, as well as ante mortem COVID-19 (n = 170) patients admitted to the University Medical Center Hamburg-Eppendorf (Hamburg, Germany). Baseline patient characteristics, parameters related to the intensive care unit (ICU) stay, and the clinical and autoptic presence of VTE were evaluated and statistically compared between groups. The occurrence of VTE in critically ill COVID-19 patients is confirmed in both ante mortem (17%) and postmortem (38%) cohorts. Accordingly, comparing the postmortem prevalence of VTE between age- and sex-matched COVID-19 (43%) and non-COVID-19 (0%) cohorts, we found the statistically significant increased prevalence of VTE in critically ill COVID-19 cohorts (p = 0.001). A change in anticoagulation practice was associated with the statistically significant prolongation of survival time (HR: 2.55, [95% CI 1.41–4.61], p = 0.01) and a reduction in VTE occurrence (54% vs. 25%; p = 0.02). In summary, in the autopsy as well as clinical cohort of critically ill patients with COVID-19, we found that VTE was a frequent finding. A change in anticoagulation practice was associated with a statistically significantly prolonged survival time